INTRODUCTION: The paper presents the results of the amino acid levels study in the vitreous body of rats with rhegmatogenous retinal detachment (RRD).
MATERIAL AND METHODS: Experimental studies were performed on 42 brown Norwegian male rats (Male Brown Norway), which were divided into 7 groups (6 animals in each group): 1 group — conditionally intact control (without retinal detachment) — animals that underwent paracentesis of the anterior chamber with the removal of its moisture and retinal puncture without the introduction of any substance under the retina; 2 group — rats, which reproduced RRD by the method (control pathology) based on the study of apoptosis induction by apoptosis-inducing factor.
RESULTS: In the group of conditionally intact control animals the concentration of amino acids in vitreous body were: alanine — 3.3 ± 0.27 ng/mL; arginine — 0.8 ± 0.1 ng/mL; aspartate — 2.3 ± 0.5 ng/mL; valine — 1.8 ± 0.8 ng/mL; histidine — 1.3 ± 0.3 ng/mL; glycine — 4.5 ± 0.8 ng/mL; glutamic acid — 1.56 ± 0.35 ng/mL; tyrosine — 0.084 ± 0.048 ng/mL; phenylalanine — 0.024 ± 0.017 ng/mL; methionine — 0.11 ± 0.1 ng/mL. In animals with model pathology of RRD was observed a significant increase in certain amino acids: the level of alanine increased 1.4 times, aspartate — 11.5 times (p < 0.05), glycine — 2.3 times (p < 0.05), glutamic acid — 7.9 times (p < 0.05) compared with rats of the conditionally intact group. Levels of other amino acids increased insignificantly.
CONCLUSIONS: The most pronounced therapeutic efficacy was found in rats treated with combination therapy with dexamethasone, resveratrol, erythropoietin, and edaravon for 7 days. The pronounced effect of combination therapy on the level of amino acids (aspartate, glutamate, alanine, and glycine) in the treatment of RRD is due to the pharmacological activity of the components of this therapeutic regimen and characterized by synergistic effects of each component in the key links of disease pathogenesis.